Valeant revenue slips even as it grapples to revive its brand

Valeant reported revenue of $1.99 billion for the first quarter of 2018, down 5% YoY
Organic revenue growth was 2%, driven by growth in the Salix business and the Bausch + Lomb/International segment.
Net loss of $2.69 billion, primarily due to a decrease in the benefit from income taxes and goodwill impairment charges.
Adjusted net income was $312 million, up 14% YoY.
Valeant also announced that it was changing its name to Bausch Health Companies Inc. effective in July 2018.
https://news.alphastreet.com/valeant-q1-2018-results/

 

The market liked something ...

 

Shorts are going to get stream rolled!!

 

must be Joes goatee cuz a pig by any side other name stinks the same